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Abstract
Purpose of Review We summarize the best evidence for statins in the prevention and treatment of heart failure.
Recent Findings In patients with cardiovascular risk factors or established atherosclerotic cardiovascular disease (but without
heart failure), statins reduce the risk of incident heart failure—mainly by preventing myocardial infarction although an additional
benefit from reducing myocardial ischemia cannot be excluded. However, in patients with established heart failure, statins do not
reduce the risk of cardiovascular death, which is mainly caused by pump failure and ventricular arrhythmias. Retrospective
analyses, however, suggest that statins may reduce the rate of heart failure hospitalization and atherosclerotic events (which are
proportionately much less common in these patients than heart failure hospitalization or death).
Summary Statin therapy should probably be continued in patients with coronary artery disease developing heart failure, although
the weak evidence and small benefit may not justify the use of this treatment in very elderly patients with a short life expectancy
and in which polypharmacy is a problem.
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Introduction
Heart failure (HF) is a clinical syndrome characterized by a
constellation of symptoms that may be accompanied by signs
caused by a structural and/or functional cardiac abnormality,
resulting in a reduced cardiac output and/or elevated intracar-
diac pressures at rest or during stress [1]. Two principal HF
phenotypes are recognized—HF with preserved ejection frac-
tion (HFpEF) and HF with reduced ejection fraction (HFrEF)
[1]. The predominant etiology of HFpEF is hypertension and
patients with this phenotype are older, more often obese, and
more likely to be women than patients with HFrEF.
Compared with HFpEF, patients with HFrEF generally are
younger, more often men, and more likely to have coronary
artery disease [2, 3].
HF can be prevented by treatment of risk factors such as
hypertension, obesity, and diabetes. Other treatments are also
effective in slowing or preventing the development of HF after
cardiac damage has occurred, e.g., the use of angiotensin-
converting enzyme inhibitors after myocardial infarction
(MI).
Cholesterol Lowering in the Context of Heart
Failure
There is a recognized “cholesterol paradox” in this cardiac
condition. That is, although raised plasma cholesterol is a
causal risk factor for coronary artery disease (CAD), low se-
rum total cholesterol is associated with poor prognosis in pa-
tients with established HF (in contrast to patients without HF)
[4–9]. The question is, of course, to what extent this counter-
intuitive relationship represents “cause and effect.” Notably,
cholesterol has an inverse correlation with disease severity
markers in other diseases (e.g., chronic kidney disease, severe
rheumatoid arthritis) which have a strong inflammatory com-
ponent [10, 11]. Thus, possible reasons for the inverse associ-
ation of cholesterol with HF are the finding that this lipid is
known to be a marker of nutritional status (perhaps in part
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linked to greater systemic inflammation) in mild to moderate
HF [12]. It is also possible that hepatic congestion (due to HF)
could impair hepatic biosynthesis of cholesterol and so lower
circulating levels since the liver is the main organ involved in
lipoprotein production [5]. Another possible explanation is
that HF causes intestinal congestion and therefore impairs
cholesterol absorption, although this remains a hypothesis,
with limited evidence [13]. In EVEREST, in 3957 patients
hospitalized for worsening HF with left ventricular ejection
fraction (LVEF) ≤ 40%, both total plasma cholesterol and tri-
glyceride exhibited a significant inverse relationship to out-
come [14], whilst follow-up of a cohort of 305 HF patients
over 20 years showed that low low-density lipoprotein
cholesterol (LDL-C) levels may predict a less favorable out-
come, especially in patients < 70 years and those on statins
[15]. Further, a lower high-density lipoprotein cholesterol is
associated with worse prognosis in HF [16], as is low serum
apolipoprotein A-I [17]. A German cohort study in 422 idio-
pathic dilated cardiomyopathy patients found that low choles-
terol levels were dependent on the severity of cardiac disease
[18], and a study of 288 very elderly patients hospitalized for
medical conditions found that low LDL-C inversely correlated
with N-terminal pro-B-type natriuretic peptide (NT-proBNP)
[19]. The current working hypothesis is that lower plasma
cholesterol is indeed secondary to the severity of patient’s
condition rather than an independent risk factor for poor out-
come [20, 21]. As noted above, this pattern is in line with other
chronic conditions and thus observational data from people
with such diseases must be interpreted with care.
Statins in the Prevention of Cardiovascular
Disease and Heart Failure
It is well established that HMG-CoA reductase inhibitors
(statins) reduce CAD events in patients with and without di-
agnosed cardiovascular (CV) disease. Clinical trial outcome
data have been subject exhaustively to meta-analysis that has
reinforced the findings of individual studies and “filled in”
any gaps in the determination of efficacy in sub-groups in
the population [22, 23]. The main findings are the consistent
demonstration that each 1.0 mmol/L reduction in LDL-C
Fig. 1 The effect of statin therapy on the risk of first non-fatal heart
failure hospitalization in 17 trials (a), heart failure death in 14 trials (b),
and first composite heart failure outcome in 14 trials (c). All heart failure
events within 30 days of myocardial infarction were excluded.
Reproduced (as permitted by terms of the CreativeCommonsAttribution
License) (http://creativecommons.org/licenses/by/4.0/) from Preiss D,
Campbell RT, Murray HM, Ford I, Packard CJ, Sattar N, et al. “The
effect of statin therapy on heart failure events: a collaborative meta-
analysis of unpublished data from major randomized trials.” Eur Heart
J. 2015;36:1536–46
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decreases the risk of major vascular events by 22%
(Cholesterol Treatment Trialists’ (CTT) Collaboration which
used individual level data on 170,000 in 26 trials) [24].
Ongoing concerns about statin therapy, particularly its safety,
were addressed comprehensively in a meta-analysis in 2017
[25]. Further, there have been recent expert reports from The
European Atherosclerosis Society (EAS) [26] and American
Heart Association [27] on the issue of muscle-related side
effects addressing their incidence rate and impact on adher-
ence. To bolster the evidence base for statin therapy, extended
follow-up data documenting safety and efficacy has become
available for a number of trials includingWOSCOPS [28, 29],
ASCOT-LLA [30], and PROSPERwhich showed that even in
the elderly, coronary protection was maintained in the long-
term (mean follow-up 8.6 years) [31]. There is, however, a
relative dearth of data from the major lipid-lowering trials on
the effects of statin therapy on prevalent HF since most trials
excluded patients with this syndrome [4, 32, 33]. For example,
4S [34] and LIPID [35] excluded patients with HF altogether,
whilst CARE [36] and HPS [37] included only patients with
mild to moderately severe symptoms and excluded those with
severely symptomatic HF. HPS showed smaller reductions in
major vascular events among those with greater baseline na-
triuretic peptide levels [38].
Some of these trials do allow us to look at incident heart
failure. Collectively, these trials provide “reasonable evi-
dence” that statin use can prevent or delay the onset of HF
[39–41]. This therapeutic link is based on the supposition that
statins prevent MI and consequent cardiac damage and so
reduce the risk of developing reduced ejection fraction HF.
A meta-analysis of 6 randomized controlled trials (RCTs) of
110,271 patient-years in patients with recent acute coronary
syndrome (ACS) showed that intensive statin therapy reduced
hospitalization rates for HF [40]. Further, in a larger collabo-
rative meta-analysis of up to 17 major primary- and
secondary-prevention randomized trials with 132,538 partici-
pants conducted over 4.3 years, statins modestly reduced the
risks of non-fatal hospitalization for HF (Fig. 1a) and the com-
posite of non-fatal hospitalization or death from HF (Fig. 1c)
but not HF death (Fig. 1b) [42••]. There was no demonstrable
difference in risk reduction between those who suffered an
incident MI or not [42••]. Interestingly, therefore, this benefit
did not seem to be due to prevention of MI preceding HF.
Retrospective examination of individual trials also pro-
vides supportive evidence for a beneficial effect of statins on
HF prevention. In 4S, simvastatin reduced incident HF by
19% [41], whilst in the post-ACS studies (PROVE IT-TIMI
22), intensive statin therapy reduced the rate of hospitalization
for HF (especially if subjects had elevated baseline B-type
natriuretic peptide (BNP)) [39], and in the TNT trial in pa-
tients with stable CAD, hospitalization for HF was lower in
the intensive statin treatment arm [43]. Even in the primary
prevention setting, if viewed over a sufficiently long time
frame, statin therapy reduced the incidence of HF endpoints.
Fig. 2 In WOSCOPS, after 20 years of follow-up, of the total of 224
subjects hospitalized for, or dying from, HF, 75 (33%) had incident MI
preceding HF, whilst 149 (67%) did not. HF events subsequent to MI
were reduced by pravastatin treatment, compared with placebo (28 vs 47)
(p = 0.022). Incident HF not preceded by MI was also less common in
pravastatin-treated patients (68 vs 81), although the difference was not
significant (p = 0.22). Abbreviations: F, fatal; HF, heart failure; MI,
myocardial infarction; NF, non-fatal; WOSCOPS, West of Scotland
Coronary Prevention Study. Footnote: In subjects who experienced HF,
the proportion with “antecedent MI” vs “no antecedent MI” does NOT
differ between placebo and pravastatin groups (p = 0.24)
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InWOSCOPS, an initial 5 years of statin therapy led to a 35%
reduction in the long-term (20-year) risk of hospitalization for
HF [44••]. Of the total of 224 subjects hospitalized for, or
dying from, HF, 75 (33%) had incident MI preceding HF,
whilst 149 (67%) did not (Fig. 2). HF events subsequent to
MI were reduced by pravastatin treatment, compared with
placebo (28 vs 47) (p = 0.022). Incident HF not preceded by
MI was also less common in pravastatin-treated patients (68
vs 81), although the difference was not significant (p = 0.22).
This is consistent with the finding in the meta-analysis above
that statins reduce HF risk through mechanisms additional to
prevention of acute MI. Serial measurement of biomarkers
such as NT-proBNP might have provided more support for
this hypothesis but, unfortunately, NT-proBNP was measured
only at 1 year after randomization in WOSCOPS [45].
Statins in the Treatment of Established Heart
Failure
Cholesterol-lowering therapy with statins is not indicated in
patients with moderate to severely symptomatic HF (New
York Heart Association (NYHA) class III-IV) according to
the 2011 European Society of Cardiology (ESC)/EAS
dyslipidemia guideline [46] and the updated 2016 ESC HF
Guidelines do not recommend initiation of statins in most
patients with HF, but continuation may be considered for
those already on statins for prevention of CAD [1]. These
recommendations are based largely on the findings of two
major outcome studies CORONA [47] and GISSI-HF [48]
that were large-scale placebo-controlled trials of statin treat-
ment in subjects with NYHA class II–IV HF. CORONA re-
cruited 5011 ischemic systolic HF patients aged ≥ 60 years,
whilst GISSI-HF included 4574 HF patients of any etiology
aged ≥ 18 years. The active treatment arm used 10 mg/day
rosuvastatin in both trials, and median follow-up was
46.8 months in GISSI-HF and 32.8 months in CORONA. In
GISSI-HF, the co-primary endpoints were time to death, and
time to death or CV hospitalization. In CORONA, the primary
endpoint was the composite of CV death, non-fatal MI, or
non-fatal stroke. No significant decrease in the primary com-
posite mortality/morbidity endpoint was seen in actively treat-
ed subjects in either trial [47, 48]. However, CORONA did
show that rosuvastat in therapy led to fewer CV
Fig. 3 Proposed mechanistic pathways on how statins reduce heart failure: (1) by reducing myocardial infarction; (2) by reducing subclinical ischemia
(e.g., statins lower troponin levels in WOSCOPS). Abbreviations: LDL, low-density lipoprotein
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hospitalizations [47], and in retrospective sub-group analyses,
rosuvastatin appeared to provide more CV benefit in those
with higher C-reactive protein [49] and lower baseline NT-
proBNP [50], and YKL-40 (chitinase-3-like protein 1) levels
[51]. When repeat events were included in the CORONA
endpoint analysis, rosuvastatin reduced hospitalization for
HF by 15–20%, but this was a post hoc analysis [52].
Not satisfied with the above trial evidence, a number of
investigators have attempted to examine if statin therapy has
any role in patients with established HF by examining random-
ized trials in a number of meta-analyses. For example, Zhang
et al. reported no significant reduction from statin therapy for
all-cause death, CV death, or rehospitalization for HF, but a
non-significant trend to lower non-fatal MI [53]. Notably, how-
ever, CAD events are relatively uncommon in HF in general,
even in ischemic HF, and are a minor contributor to the overall
morbidity andmortality in patients with this condition [54]. The
same group also investigated whether statin therapy had an
effect onmeasures of left ventricular size and function, this time
collating 11 RCTs totaling 590 patients [55]. Here they reported
that statin use increased LVEF by 3% but notably, some of the
trials were of modest quality, and there was considerable het-
erogeneity in the findings, so definitive conclusions cannot be
made. Thus, whilst the best evidence suggests statins do not
improve outcomes in patients with HF, clinicians generally
continue HF patients on statins as most are not comfortable
stopping them, unless statin-related complications arise.
Potential Mechanisms by Which Statins
Prevent HF Development
Statins are believed to lower CAD by stabilizing atheromatous
plaques, reduction of atheroma volume, and prevention of for-
mation of new atherosclerotic lesions resulting in fewer MIs
and less associated cardiac tissue damage. Thismay be themain
way statins lower incident HF. We looked further at this in the
long-term follow-up of WOSCOPS (Fig. 2) where, as noted
before, it appeared that statin use decreased the incidence of
HF. In a companion report, we found that pravastatin reduced
high-sensitivity troponin I concentration by 13% [56•]—and
troponins also predict incident HF. Thus, it is theoretically pos-
sible that statins lessen “subclinical” ischemia and cardiac dam-
age (Fig. 3). Whilst others have proposed a number of pleiotro-
pic actions of statins (e.g., anti-inflammatory), there is no clear
evidence for this contributing to clinical benefit [57].
Non-Statin Lipid-Lowering Therapies
in the Prevention of Heart Failure
PCSK9 inhibitors have not been found to affect HF
hospitalisation (OR 0.98; 95% CI 0.86–1.13; P = 0.79) in a
meta-analysis of 23 RCTs of 42,151 participants [58]. One
ezetimibe randomized trial (HIJ-PROPER) of patients with
acute coronary syndrome and dyslipidemia showed that HF
hospitalisation was reduced in the intensive (pitavastatin +
ezetimibe) vs. standard (pitavastatin monotherapy) lipid-low-
ering group, although the number of events was small (n = 59)
and the 95% confidence interval around the estimate of treat-
ment effect wide (HR 0.47; 95% CI 0.27–0.81; P = 0.006)
[59]. The ACCORD and ACCORDION trial of fenofibrate
showed no significant effect on congestive HF [60]. There
are no robust data of the effect of niacin on HF.
Conclusions and Clinical Implications
There is robust evidence that in addition to lowering coronary
heart disease (CHD), statins also lower risk for incident HF
both in the medium and long term, although the extent of risk
reduction is modest and far lower than the comparable bene-
fits on CHD outcomes. By contrast, in patients with
established HF, best evidence from two landmark trials does
not support improved clinical outcomeswith statins. Although
statins may also lessen the chances of subsequent CAD events
in HF patients (for which there is limited evidence in a meta-
analysis of RCTs), few patients with HF actually die from
acute CAD events and existing evidence is far from conclu-
sive. Nevertheless, most clinicians generally do not stop
statins in patients already prescribed these drugs and who
subsequently develop HF. However, more judicious use of
statins in the elderly HF patient with polypharmacy and a
shorter life expectancy appears to be sensible.
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